Hemophilia A - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hemophilia A - Overview 7
Hemophilia A - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Hemophilia A - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Hemophilia A - Companies Involved in Therapeutics Development 25
Alnylam Pharmaceuticals Inc 25
Amarna Therapeutics BV 25
Apitope International NV 25
Bayer AG 26
BioMarin Pharmaceutical Inc 26
Bioverativ Inc 27
Catalyst Biosciences Inc 27
Chugai Pharmaceutical Co Ltd 28
CSL Ltd 28
DBV Technologies SA 29
Dimension Therapeutics Inc 29
Emergent BioSolutions Inc 30
EpiVax Inc 30
Expression Therapeutics LLC 31
Green Cross Corp 31
Idogen AB 32
Immusoft Corp 32
Lentigen Technology Inc 32
mAbxience SA 33
Novo Nordisk A/S 33
OPKO Biologics Ltd 34
Pangen Biotech Inc. 34
Pfizer Inc 34
Pharming Group NV 35
Promethera Biosciences SA 35
rEVO Biologics Inc 36
Sangamo Therapeutics Inc 36
Shire Plc 36
SK Chemicals Co Ltd 37
Spark Therapeutics Inc 38
UniQure NV 38
XL-protein GmbH 39
Hemophilia A - Drug Profiles 40
antihemophilic factor (recombinant) - Drug Profile 40
antihemophilic factor (recombinant) - Drug Profile 41
antihemophilic factor (recombinant) - Drug Profile 42
antihemophilic factor (recombinant) - Drug Profile 43
antihemophilic factor (recombinant) - Drug Profile 44
antihemophilic factor (recombinant) - Drug Profile 45
antihemophilic factor (recombinant) biosimilar - Drug Profile 46
antihemophilic factor (recombinant) biosimilar - Drug Profile 47
antihemophilic factor (recombinant) biosimilar - Drug Profile 48
antihemophilic factor (recombinant), PEGylated - Drug Profile 49
antihemophilic factor (recombinant), pegylated - Drug Profile 54
antihemophilic factor (recombinant), porcine sequence - Drug Profile 57
antihemophilic factor (recombinant), single chain - Drug Profile 61
ATXF-8117 - Drug Profile 65
BAX-888 - Drug Profile 66
BAY-1093884 - Drug Profile 67
BIVV-001 - Drug Profile 68
BMN-270 - Drug Profile 70
Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile 72
coagulation factor VIIa (recombinant) - Drug Profile 73
concizumab - Drug Profile 75
CSL-689 - Drug Profile 77
damoctocog alfa pegol - Drug Profile 79
Deimmunized FVIII - Drug Profile 81
DTX-201 - Drug Profile 82
emicizumab - Drug Profile 83
ET-3 - Drug Profile 86
fitusiran - Drug Profile 87
Gene Therapy for Hematological Disorders - Drug Profile 95
Gene Therapy for Hemophilia A - Drug Profile 96
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 97
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 98
HepaStem - Drug Profile 99
IN-3012 - Drug Profile 102
Kovaltry - Drug Profile 104
LG-889 - Drug Profile 107
LR-769 - Drug Profile 108
marzeptacog alfa - Drug Profile 111
MG-1113A - Drug Profile 114
MOD-5014 - Drug Profile 115
Monoclonal Antibody for Hemophilia A - Drug Profile 118
PBB-8-IN - Drug Profile 119
PF-06741086 - Drug Profile 120
Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile 121
Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile 122
Recombinant Protein to Replace Coagulation Factor VIII for Hemophilia A - Drug Profile 123
Recombinant Proteins for Hemophilia A - Drug Profile 124
SB-525 - Drug Profile 125
SEL-201 - Drug Profile 127
SHP-656 - Drug Profile 128
SPK-8011 - Drug Profile 130
SVF-VIIa - Drug Profile 132
Hemophilia A - Dormant Projects 133
Hemophilia A - Discontinued Products 135
Hemophilia A - Product Development Milestones 136
Featured News & Press Releases 136
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 146
Disclaimer 147

List of Tables

Number of Products under Development for Hemophilia A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2017
Hemophilia A - Pipeline by Apitope International NV, H1 2017
Hemophilia A - Pipeline by Bayer AG, H1 2017
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
Hemophilia A - Pipeline by Bioverativ Inc, H1 2017
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2017
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Hemophilia A - Pipeline by CSL Ltd, H1 2017
Hemophilia A - Pipeline by DBV Technologies SA, H1 2017
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Emergent BioSolutions Inc, H1 2017
Hemophilia A - Pipeline by EpiVax Inc, H1 2017
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2017
Hemophilia A - Pipeline by Green Cross Corp, H1 2017
Hemophilia A - Pipeline by Idogen AB, H1 2017
Hemophilia A - Pipeline by Immusoft Corp, H1 2017
Hemophilia A - Pipeline by Lentigen Technology Inc, H1 2017
Hemophilia A - Pipeline by mAbxience SA, H1 2017
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2017
Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2017
Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2017
Hemophilia A - Pipeline by Pfizer Inc, H1 2017
Hemophilia A - Pipeline by Pharming Group NV, H1 2017
Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2017
Hemophilia A - Pipeline by rEVO Biologics Inc, H1 2017
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Shire Plc, H1 2017
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2017
Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by UniQure NV, H1 2017
Hemophilia A - Pipeline by XL-protein GmbH, H1 2017
Hemophilia A - Dormant Projects, H1 2017
Hemophilia A - Dormant Projects, H1 2017 (Contd..1), H1 2017
Hemophilia A - Discontinued Products, H1 2017